Apotex will pay $39.1 million while Heritage Pharmaceuticals will contribute $10 million to 50 states and U.S. territories. The settlements, resulting from complaints involving plaintiffs from those states and territories, require both companies to cooperate with multistate litigation in Connecticut District Court, which targets 30 corporate defendants and 25 executives.
The settlements arise from three antitrust complaints against pharmaceutical companies and executives related to different sets of generic drugs. The first trial related to those complaints is set to take place in Hartford, Conn., concerning 80 topical generic drugs that reportedly generated billions in revenue.
Read more here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.